GlassScriptPhysician profile
Bradley Tanner
NPI 1588396964
$1,206.66
in general payments reported to CMS, 2019-2025
17 companies · $536 in 2025
The $536 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $155 · 2024: $515 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188 · Entertainment: $18.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.17 |
| Entertainment | $18.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $176.92 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $165.53 | 2023-2025 | Rexulti |
| Eisai INC. | $154.91 | 2024-2025 | |
| Lilly USA, LLC | $101.99 | 2023-2025 | Kisunla, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $89.25 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Sumitomo Pharma America, INC. | $83.29 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.01 | 2025 | Caplyta |
| Abbvie INC. | $70.42 | 2023-2024 | |
| Amgen INC. | $61.96 | 2024-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $57.76 | 2023-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $40.10 | 2024-2025 | Cologuard Collection Kit |
| Averitas Pharma INC. | $33.28 | 2023 | Qutenza |
| Radius Health, INC. | $24.85 | 2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $22.80 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $18.69 | 2025 | Korlym |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $18.49 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.41 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.